Cella et al reported the ONKOTEV score to predict venous thromboembolism (VTE) in a cancer patient. This can help to identify a patient who may benefit from more aggressive management. The authors are from multiple institutions in Italy and Germany participating in the ONKOTEV-2 Study.
Patient selection: cancer patient
Parameters:
(1) Khorana score for chemotherapy-associated thrombosis (from 0 to 6)
(2) history of previous venous thromboembolism
(3) metastatic tumor
(4) macroscopic compression of vessel (vascular or lymphatic)
Parameter
Finding
Points
Khorana score
0 or 2
0
3 to 6
1
history of previous VTE
no
0
yes
1
metastatic tumor
no
0
yes
1
macroscopic vessel compression
no
0
yes
1
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
Total Score
1-Year VTE Risk
0
3.7%
1
9.7%
2
19.4%
3 or 4
33.9%
Performance:
• The area under the ROC curve is 0.72 at 3 months and 0.75 at 6 months.
To read more or access our algorithms and calculators, please log in or register.
